Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00201_DB06213_nanopub.RAxFhxY2UcV46qjnbvCLZhQ0-WpcDSDd3jN8q2hG5Xguo#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00201_DB06213 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00201_DB06213 label "DDI between Caffeine and Regadenoson - Caffeine may diminish the vasodilatory effect of Regadenoson. Regadenoson prescribing information recommends avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior the the administration of regadenoson. The impact of low doses of caffeine-containing products such as coffee, tea, and colas is unclear. [drugbank_resource:DB00201_DB06213]" assertion.
- drugbank_resource:DB00201_DB06213 identifier "drugbank_resource:DB00201_DB06213" assertion.
- drugbank_resource:DB00201_DB06213 title "DDI between Caffeine and Regadenoson - Caffeine may diminish the vasodilatory effect of Regadenoson. Regadenoson prescribing information recommends avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior the the administration of regadenoson. The impact of low doses of caffeine-containing products such as coffee, tea, and colas is unclear." assertion.
- drugbank:DB00201 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00201_DB06213 assertion.
- drugbank:DB06213 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00201_DB06213 assertion.